Evidence map›Paper›PMID 41055859›Full record

ArticleCardiovascular drugs and therapy2026

Relationship Between the Incidence of Metabolic Syndrome and Breast Cancer.

Naoki Kimoto, Yohei Miyashita, Yutaka Yata, Takeshi Aketa, Masami Yabumoto, Yasushi Sakata, Takashi Washio, Seiji Takashima, Masafumi Kitakaze

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Naoki Kimoto *Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, 2-2, Suita, Osaka, Yamadaoka,, 565-0871, Japan.
Yohei Miyashita *Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita Osaka, Japan.
Yutaka YataHanwa Memorial Hospital, Minamisumiyoshi, 3-5-8, Sumiyoshi-Ku, Osaka, Japan.
Takeshi AketaASCLEPIUS INC. , 3-6-2 Minamisumiyoshi, Sumiyoshi-Ku, Osaka, Japan.
Masami YabumotoHanwa Memorial Hospital, Minamisumiyoshi, 3-5-8, Sumiyoshi-Ku, Osaka, Japan.
Yasushi SakataDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita Osaka, Japan.
Takashi WashioThe Institute of Scientific and Industrial Research, Osaka University, 1-1 Yamadaoka, Osaka, Suita, Japan.
Seiji TakashimaDepartment of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, 2-2, Suita, Osaka, Yamadaoka,, 565-0871, Japan.
Masafumi KitakazeDepartment of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, 2-2, Suita, Osaka, Yamadaoka,, 565-0871, Japan. kitakaze.masafumi@kinshukai.or.jp.ORCID 0000-0001-5157-4213

Funding

Japan Heart Foundation Grant to Kitakaze
6 · The paper itself

Abstract

purposeBreast cancer affects females from puberty onward, with incidence rates increasing with age. Although metabolic syndrome (MetS) has reportedly increased the incidence of almost all cancers, no clear consensus on the role of MetS in breast cancer development exists. We aimed to clarify the effects of MetS on breast cancer incidence.

methodsTo investigate this relationship, we analyzed Japanese healthcare data of females from 2005 to 2020 and examined the incidence of breast cancer. MetS was evaluated based on the Japanese criteria or the NCEP ATP III guidelines at enrollment. Of 1,144,791 participants without missing data in our general public cohort, 32,775 with breast cancer at the beginning of the observation period were excluded; 54,330 participants with breast cancer were identified during the observation period.

resultsBoth pre-stage MetS and MetS, defined using the Japanese criteria, were associated with the less frequent incidence of breast cancer (hazard ratios [HRs], 0.90; 95% CI, 0.86-0.94; p < 0.005: HR, 0.83; 95% CI, 0.80-0.87; p < 0.005). Furthermore, MetS using NCEP ATP III was associated with the lower HR (0.87: CI, 0.84-0.90; p < 0.005), and the number of the factors from 1 to 5 was gradually associated with the lower HRs. Analysis according to age group revealed that this observation was the most prominent in the < 50-year-old group.

conclusionMetS is associated with the less frequent breast cancer incidence in females, especially aged < 50 years.

Indexed as

Breast NeoplasmsMetabolic SyndromeAdultAgedFemaleHumansIncidenceJapanMiddle AgedRisk AssessmentRisk FactorsAgeBig dataBreast cancerEarly stage of metabolic syndromeMetabolic syndrome

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.